• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Diagnostics » Artificial intelligence

Artificial intelligence
Artificial intelligence RSS Feed RSS

Head filled with digital data

Riken AI creates and communicates ‘newborn’ knowledge of prostate cancer to humans

Jan. 8, 2020
By Annette Boyle
Researchers at the Riken Center for Advanced Intelligence Project in Japan developed artificial intelligence (AI) technology that found previously unknown features related to prostate cancer occurrence in unannotated pathology images.
Read More
1-2-zebra-medical-healthpnx.png

Depuy, Zebra Medical partner to develop orthopedic tools to create 3D images from X-ray

Jan. 2, 2020
By Stacy Lawrence
Israeli startup Zebra Medical Vision Ltd. has partnered with Johnson & Johnson’s Depuy Synthes to develop artificial intelligence (AI)-based algorithms to reduce the costs and radiation risks associated with imaging to prepare for orthopedic surgery.
Read More
1-2-imedtac-faceme.png

Cyberlink wades into health care with facial recognition technology for drug dispensers

Jan. 2, 2020
By Meg Bryant
Drug diversion in hospitals is a serious concern, facilitated in part by inadequate security controls that allow unauthorized staff to access the pharmacy stock. To help thwart this problem and improve medication management, Taipei, Taiwan-based Cyberlink Corp. and Imedtac Co. Ltd. are teaming up to bring facial recognition technology to the hospital medicine cabinet.
Read More

Cyberlink wades into health care with facial recognition technology for drug dispensers

Jan. 2, 2020
By Meg Bryant
Drug diversion in hospitals is a serious concern, facilitated in part by inadequate security controls that allow unauthorized staff to access the pharmacy stock. To help thwart this problem and improve medication management, Taipei, Taiwan-based Cyberlink Corp. and Imedtac Co. Ltd. are teaming up to bring facial recognition technology to the hospital medicine cabinet.
Read More

South Korea improves innovative medical device policies, but more needed

Dec. 31, 2019
By Jihyun Kim
HONG KONG – Aiming to attract more active innovation to its medical device industry, South Korea updated some of its industry regulations through 2019. The ultimate goal was to make it easier for advanced medical technologies that use artificial intelligence (AI), robotics and 3D printing that have yet to penetrate the market due to inefficient approval processes.
Read More
Escherichia coli bacteria

Biotia leverages next-gen sequencing, AI in battle against HAIs

Dec. 30, 2019
By Meg Bryant
Health care-associated infections (HAI) pose a constant challenge for hospitals and health systems, resulting in increased morbidity and mortality and billions in costs each year. According to the Centers for Disease Control and Prevention, about 1 in 31 patients has at least one HAI at any given time. In 2016, the U.S. Department of Health and Human Services set a 2020 goal of reducing HAIs by 50% below a 2015 baseline. To that end, Biotia Inc. plans to launch an artificial intelligence (AI)-enabled test to detect harmful bugs and antimicrobial resistance (AMR) early in the new year.
Read More
pentax-medical-discover-12-24.png

Pentax Medical gets CE mark for AI-based polyp detector Discovery

Dec. 24, 2019
By Jihyun Kim
HONG KONG – Pentax Medical Co., of Tokyo, has gained CE marking for its artificial intelligence-based polyp detector Discovery. The detector assists endoscopists in finding potential polyps during a colorectal examination. The software has been trained using more than 120,000 files from about 300 clinical cases.
Read More
Eko Devices Inc.,

Eko scores FDA breakthrough status for ECG-based algorithm

Dec. 18, 2019
By Meg Bryant
Heart failure is a leading cause of disability and death in the U.S., but many cases are diagnosed late due to limited access to echocardiography, the primary method of detecting the condition. To address that need, the U.S. FDA has granted breakthrough device designation to Eko Devices Inc., of Berkeley, Calif., for an electrocardiogram (ECG)-based algorithm that could serve as an easily accessible screening tool for heart failure during routine physical exams.
Read More
France-Verlingue-DITEP-12-16.png

French-based data science team develops AI tool for predicting cancer drug approval following phase I trials

Dec. 16, 2019
By Bernard Banga
PARIS – A team of medical researchers and engineers from the Gustave Roussy Institute, in Villejuif, France, and Paris-Sud University recently developed an artificial intelligence system called Resolved2, designed to assess prospective cancer drugs. As Loïc Verlingue, lead cancer specialist on the data science team at the Gustave Roussy Institute, explained to BioWorld MedTech, “this AI is intended to predict efficiently whether a cancer treatment molecule will achieve authorization or not within six years of pharmacological data and phase I clinical trials.”
Read More

Caris launches AI-based genomic profiling test to clarify cancer of unknown primary origin

Dec. 12, 2019
By Stacy Lawrence
Irving, Texas-based Caris Life Sciences Inc. has launched an AI-based genomic profiling test to better characterize cases of cancer of unknown primary origin (CUP) and atypical cases and offer appropriate treatment options. Known as the MI GPS (Genomic Profiling Similarity) Score, the analysis is based on an AI analysis of a 592-gene panel of all the clinically relevant genetic biomarkers for cancer.
Read More
Previous 1 2 … 48 49 50 51 52 53 54 55 56 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 19, 2025.
  • Lifebuoy with financial graphs

    CSL to shave off 3,000 jobs, Seqirus vaccine unit

    BioWorld
    CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than...
  • Illustration of magnifying glass inspecting brain

    Subtyping beats a path toward precision medicine in Alzheimer’s

    BioWorld MedTech
    Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding subtypes in Alzheimer’s disease is all...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for August 19, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe